Systemic Levels of Anti-VEGF: What Available Data Reveal

Robert Avery MD, PhD

Show Description +

Robert L. Avery, MD, discusses the recent finding from CATT, IVAN on systemic concentrations of bevacizumab and ranibizumab after injection, the EPAR report in regard to the systemic safety of aflibercept, and his own study on serum levels of anti-VEGF drug levels (bevacizumab, ranibizumab, and aflibercept) and free VEGF in human plasma.

Posted: 1/16/2014

Keywords:

Age-Related Macular Degeneration (AMD)

•

Age-Related Macular Degeneration (AMD)

•

Anti-VEGF

•

Bevacizumab

•

Diabetic macular edema, DME

•

Ranibizumab

•

Retina

Up Next

Name: Systemic Levels of Anti-VEGF: What Available Data Reveal
Uploaded: 2014-01-16T16:57:00+00:00
Description: Robert L. Avery, MD, discusses the recent finding from CATT, IVAN on systemic concentrations of bevacizumab and ranibizumab after injection, the EPAR report in regard to the systemic safety of aflibercept, and his own study on serum levels of anti-VEGF drug levels (bevacizumab, ranibizumab, and aflibercept) and free VEGF in human plasma.